Jean-Yves Bonnefoy

Alsace BioValley Association operates as a health innovation center. The private company is based in Illkirch, France.

Based in Lyon within the Center of excellence in Infectious Diseases, Platine Pharma Services is an essential source of immune information for scientists and clinicians. From protocol support to regulatory reports, the company designs, performs and interprets complex molecular and cellular assays. Platine actively supports the development of in-vitro diagnostic, cosmetic and therapeutic product candidates, highlighting key markers and features in both normal and pathological conditions, and guiding decisions at each development stage. Using state-of-the-art technologies such as multi-parametric flow cytometry, Singulex, Luminex, Mesoscale Discovery, ELISpot or ELISA, Platine Pharma Services offers a fit-for-purpose approach to its customers and partners.

Transgene Tasly (Tianjin) Biopharmaceutical Co., Ltd. engages in theresearch and development, and manufacture of immunotherapies for the treatment of oncology and infectious diseases. Its business scope includes biopharmaceutical technology development, technology transfer, and related technical advisory services. The company was founded on July 26, 2010 and is headquartered in Tianjin, China.

ElsaLys Biotech SAS provides therapeutic monoclonal antibody player services. It involves in cellular events at the core of the pathological process: immune response, angiogenesis, survival, proliferation, adhesion and migration. The company also designs and develops a new generation of antibodies that target tumors and their immune microenvironment. ElsaLys Biotech was founded by Christine Guillen, Thierry Menguy, Vanessa Duong, and Martine Brandt in 2013 and is headquartered in Lyon, France.

Anagenesis Biotechnologies SAS operates as a preclinical-stage stem cell-based company. It focuses on developing novel treatments for genetic and age-related muscle degenerative diseases with unmet medical needs. The firm offers cell therapy for genetic diseases and pharmacological drugs for genetic and age-related diseases. The company was founded by Jean-Yves Bonnefoy, Christopher Henderson, Thierry Noel, Olivier Pourquié, Marie Knockaert and Jérôme Chal on April 25, 2011 and is headquartered in Graffenstaden, France.

Syndivia SAS engages in the development of treatment for cancer. Its product pipeline include SDV1001, for pancreatic cancer, colorectal cancer and TNBC; and SDV1101, for breast cancer and liposarcoma. The company is headquartered in Illkirch, France.